申请人:Crooks A. Peter
公开号:US20060009468A1
公开(公告)日:2006-01-12
A method for the treatment of cancer that includes in vivo delivering a sensitizer to a patient that has cancer; and exposing the patient to ionizing radiation, hyperthermia or an anticancer chemotherapeutic agent, or combinations of these agents. The sensitizer may be a structural analog of L-arginine, such as L-Canavanine or an ester prodrug of structural analogs of L-arginine, such as an ester of L-Canavanine. The chemotherapeutic agent may include DNA-interactive agents such as alkylating agents, e.g. cisplatin, cyclophosphamide, altretamine; DNA strand-breakage agents, such as bleomycin; intercalating topoisomerase II inhibitors, eg., dactinomycin and doxorubicin); nonintercalating topoisomerase II inhibitors such as, etoposide and teniposide; and the DNA minor groove binder plicamydin, for example.
一种治疗癌症的方法,包括向患有癌症的病人体内输送增敏剂;并使病人接受电离辐射、热疗或抗癌化疗剂或这些制剂的组合。增敏剂可以是 L-精氨酸的结构类似物,如 L-卡瓦宁或 L-精氨酸结构类似物的酯原药,如 L-卡瓦宁的酯。化疗剂可包括 DNA 干扰剂,如烷化剂,如顺铂、环磷酰胺、阿曲他胺;DNA 链断裂剂,如博来霉素;交联拓扑异构酶 II 抑制剂,如达托霉素和多柔比星;非交联拓扑异构酶 II 抑制剂,如依托泊苷和替尼泊苷;以及 DNA 小沟粘合剂 plicamydin 等。